Stuart Chaffee

Company: QuantX Biosciences

Job title: Chief Executive Officer

Bio:

Stuart Chaffee, PhD is the Chief Executive Officer of QuantX Biosciences, a pre-clinical stage small molecule immunology company. Prior to QuantX, he was an Entrepreneur in Residence at Atlas Venture, and was Chief Business Officer at Affinivax until its sale to GSK. Stuart has helped start a number of venture-backed biotech companies, including Kymera Therapeutics, Praxis Medicines, and Zafgen. Stuart hold a BS in chemistry from The College of William and Mary, a PhD in organic chemistry from Yale University, and an MBA in finance from the Wharton School. 

Seminars:

Uncovering Modality, Precision Targeting & Global Partnership Synergies to Advance Autoimmune Combination Therapy Innovations 3:00 pm

Discussing optimal modality combinations, considering checkpoint agonism, bispecific, monoclonal and fixed dose oral approaches, to safety tailor combinations for complex autoimmune diseases, including IBD and RA Evaluating the balance of known and novel targets to align with safety profiles and unmet patient needs Exploring partnership opportunities with the rapidly expanding bispecific market in Asia and…Read more

day: Day Two